MIRA (Mira Pharmaceuticals) 3-Year Share Buyback Ratio: -41.70% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIRA Mira Pharmaceuticals Inc MIRA
31 GF Score
Price $0.72
! 1 Warning Sign
View Full Analysis

What is Mira Pharmaceuticals 3-Year Share Buyback Ratio?

Mira Pharmaceuticals MIRA -0.36% 31 3-Year Share Buyback Ratio is -41.70 as of Jun. 2026. GuruFocus rates MIRA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 646 Drug Manufacturers companies, Mira Pharmaceuticals ranks worse than 90.71% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Mira Pharmaceuticals's current 3-Year Share Buyback Ratio was -41.70%.

The historical rank and industry rank for Mira Pharmaceuticals's 3-Year Share Buyback Ratio or its related term are showing as below:

MIRA' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -41.7   Med: -22.8   Max: -3.9
Current: -41.7

During the past 5 years, Mira Pharmaceuticals's highest 3-Year Share Buyback Ratio was -3.90%. The lowest was -41.70%. And the median was -22.80%.

MIRA's 3-Year Share Buyback Ratio is ranked worse than
90.71% of 646 companies
in the Drug Manufacturers industry
Industry Median: -2.1 vs MIRA: -41.70

Mira Pharmaceuticals (NAS:MIRA) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Mira Pharmaceuticals 3-Year Share Buyback Ratio Related Terms


MIRA vs SCLX, MDCX, NSRX: 3-Year Share Buyback Ratio Comparison

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mira Pharmaceuticals 3-Year Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's 3-Year Share Buyback Ratio falls into.


MIRA
31GF Score
Mira Pharmaceuticals Inc MIRA
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mira Pharmaceuticals 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -41.70 mean?
Mira Pharmaceuticals (MIRA) has a 3-Year Share Buyback Ratio of -41.70 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Mira Pharmaceuticals and its competitors. According to the industry distribution chart, Mira Pharmaceuticals ranks #586 out of 646 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Mira Pharmaceuticals' 3-Year Share Buyback Ratio too high?
Mira Pharmaceuticals' current 3-Year Share Buyback Ratio is -41.70. Based on the distribution chart, Mira Pharmaceuticals ranks #586 out of 646 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mira Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' 3-Year Share Buyback Ratio compare to SCLX and MDCX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #586 out of 646 companies for 3-Year Share Buyback Ratio. This places Mira Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Mira Pharmaceuticals and its competitors. Mira Pharmaceuticals's current 3-Year Share Buyback Ratio is -41.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current 3-Year Share Buyback Ratio of -41.70. The current 3-Year Share Buyback Ratio is -41.70. Mira Pharmaceuticals' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current 3-Year Share Buyback Ratio is -41.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mira Pharmaceuticals Business Description

Other Exchanges K6S:Germany
Address 1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
31GF Score

Get the complete analysis for MIRA

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price